Altravax, Inc. announced that it has been awarded two SBIR grants totaling $1.2 million from the NIH's National Institute of Allergy and Infectious Diseases for research on antibody-inducing vaccines for HIV-1. A 2009 report from the United Nations has estimated the total number of people living with AIDS is now at over 30 million. Altravax will use its proprietary MolecularBreeding™ directed evolution technology to create vaccines that provide broad protection against the various strains of HIV-1... 
More...
More...